United Kingdom

People: Anthem Inc (ANTM.N)

ANTM.N on New York Stock Exchange

19 Jul 2019
Change (% chg)

$-2.45 (-0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Tallett, Elizabeth 

Ms. Elizabeth E. Tallett is Chairman of the Board of Anthem, Inc., effective May 16, 2018. She has been a director of the Company since October 2013. She was a principal of Hunter Partners, LLC (health care consulting) from June 2002 to February 2015. Ms. Tallett continues to operate as a consultant to health care companies. Previously, Ms. Tallett was President and Chief Executive Officer of Transcell Technologies, Inc. (specialty pharmaceuticals), President of Centocor Pharmaceuticals (biotechnology), member of the Parke-Davis (pharmaceuticals) Executive Committee and Director of Worldwide Strategic Planning for Warner-Lambert Company (pharmaceuticals). Ms. Tallett has served as a director of Meredith Corporation (magazine publisher) since 2008, Principal Financial Group, Inc. (financial services) since 1992 (as presiding director since 2007) and Qiagen, N.V. (biotechnology research equipment manufacturing) since 2011. She previously served as a director of Coventry Health Care, Inc. (health insurance) from 1998 to 2013 (including serving as lead director) and IntegraMed America, Inc. (outpatient health clinics) from 1998 to 2012. Ms. Tallett brings significant CEO, finance, health care industry, insurance industry and marketing and public relations experience to the Board from her chief executive, other management and board positions in several health care, insurance and pharmaceutical organizations. These positions also provided her with regulatory and governmental experience due to the highly regulated nature of these organizations. She also has environmental, social and governance experience, having served as a presiding or lead director and as a member of the governance committees of several public companies.

Basic Compensation

Total Annual Compensation, USD 143,181
Restricted Stock Award, USD 174,923
Long-Term Incentive Plans, USD --
All Other, USD 6,500
Fiscal Year Total, USD 324,604

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --